BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 12057912)

  • 1. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.
    Wistuba II; Ashfaq R; Maitra A; Alvarez H; Riquelme E; Gazdar AF
    Am J Pathol; 2002 Jun; 160(6):2073-9. PubMed ID: 12057912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma.
    Riquelme E; Tang M; Baez S; Diaz A; Pruyas M; Wistuba II; Corvalan A
    Cancer Lett; 2007 May; 250(1):100-6. PubMed ID: 17084965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma.
    Moreno M; Pimentel F; Gazdar AF; Wistuba II; Miquel JF
    Ann Hepatol; 2005; 4(3):192-9. PubMed ID: 16177659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
    Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
    Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints.
    Wistuba II; Behrens C; Virmani AK; Mele G; Milchgrub S; Girard L; Fondon JW; Garner HR; McKay B; Latif F; Lerman MI; Lam S; Gazdar AF; Minna JD
    Cancer Res; 2000 Apr; 60(7):1949-60. PubMed ID: 10766185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma.
    Wistuba II; Tang M; Maitra A; Alvarez H; Troncoso P; Pimentel F; Gazdar AF
    Cancer Res; 2001 May; 61(9):3795-800. PubMed ID: 11325854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
    Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
    Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
    Ismail HM; Medhat AM; Karim AM; Zakhary NI
    Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
    Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
    Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
    Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
    Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allelic loss and down-regulation of FHIT gene expression in esophageal squamous cell carcinoma].
    Liu FX; Huang XP; Zhao CX; Xu X; Han YL; Cai Y; Wu RL; Wu M; Zhan QM; Wang MR
    Ai Zheng; 2004 Sep; 23(9):992-8. PubMed ID: 15363189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma.
    Wistuba II; Behrens C; Milchgrub S; Bryant D; Hung J; Minna JD; Gazdar AF
    Oncogene; 1999 Jan; 18(3):643-50. PubMed ID: 9989814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragile histidine triad (FHIT) gene and its association with p53 protein expression in the progression of gall bladder cancer.
    Priya TP; Kapoor VK; Krishnani N; Agrawal V; Agarwal S
    Cancer Invest; 2009 Aug; 27(7):764-73. PubMed ID: 19452299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas.
    Gray SE; Kay E; Leader M; Mabruk M
    J Cutan Pathol; 2008 Sep; 35(9):816-25. PubMed ID: 18494825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus.
    Velickovic M; Delahunt B; Grebe SK
    Cancer Res; 1999 Mar; 59(6):1323-6. PubMed ID: 10096566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
    Singh RB; Amare Kadam PS
    Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma.
    Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M
    Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.